Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap
Annovis Bio (NYSE: ANVS) has secured a U.S. patent for treating acute traumatic brain injuries (TBI) with its lead drug candidate, buntanetap. The patent (No. 12,042,482) covers methods for treating TBI and preventing nerve cell death. This achievement strengthens Annovis Bio's portfolio, which includes patents for using buntanetap in acute and chronic neurodegenerative diseases and mental illnesses.
CEO Maria Maccecchini highlighted the significance of this milestone, emphasizing buntanetap's potential to address nerve cell death in various brain conditions. Preclinical studies in TBI and stroke animal models have shown buntanetap's efficacy in preventing cell death and loss of function, demonstrating its potential benefits for brain trauma victims.
Annovis Bio (NYSE: ANVS) ha ottenuto un brevetto statunitense per il trattamento di lesioni cerebrali traumatiche acute (TBI) con il suo principale candidato farmaco, buntanetap. Il brevetto (No. 12,042,482) copre metodi per trattare le TBI e prevenire la morte delle cellule nervose. Questo traguardo rafforza il portafoglio di Annovis Bio, che include brevetti per l'uso di buntanetap in malattie neurodegenerative acute e croniche e disturbi mentali.
Il CEO Maria Maccecchini ha sottolineato l'importanza di questo traguardo, evidenziando il potenziale di buntanetap nell'affrontare la morte delle cellule nervose in diverse condizioni cerebrali. Studi preclinici su modelli animali di TBI e ictus hanno mostrato l'efficacia di buntanetap nel prevenire la morte cellulare e la perdita di funzionalità, dimostrando i suoi potenziali benefici per le vittime di traumi cerebrali.
Annovis Bio (NYSE: ANVS) ha obtenido una patente estadounidense para el tratamiento de lesiones cerebrales traumáticas agudas (TBI) con su candidato a fármaco principal, buntanetap. La patente (No. 12,042,482) cubre métodos para tratar las TBI y prevenir la muerte de las células nerviosas. Este logro fortalece la cartera de Annovis Bio, que incluye patentes para el uso de buntanetap en enfermedades neurodegenerativas agudas y crónicas y trastornos mentales.
La CEO Maria Maccecchini subrayó la importancia de este hito, enfatizando el potencial de buntanetap para abordar la muerte celular nerviosa en diversas condiciones cerebrales. Estudios preclínicos en modelos animales de TBI y accidente cerebrovascular han mostrado la eficacia de buntanetap para prevenir la muerte celular y la pérdida de función, demostrando sus posibles beneficios para las víctimas de traumas cerebrales.
안노비스 바이오(NYSE: ANVS)는 주요 후보 약물인 부탄타팁을 사용하여 급성 외상성 뇌손상(TBI) 치료를 위한 미국 특허를 확보했습니다. 이 특허(번호 12,042,482)는 TBI 치료와 신경 세포 사멸 방지 방법을 다룹니다. 이 성과는 부탄타팁을 급성 및 만성 신경퇴행성 질환과 정신 질환에 사용하기 위한 특허를 포함한 안노비스 바이오의 포트폴리오를 강화합니다.
CEO 마리아 마체키니는 이 이정표의 중요성을 강조하면서, 부탄타팁이 다양한 뇌 상태에서 신경 세포 사멸 문제를 해결할 수 있는 잠재력을 가지고 있다고 언급했습니다. 전임상 연구는 TBI 및 뇌졸중 동물 모델에서 부탄타팁의 세포 사멸 및 기능 상실 예방 효과를 보여주어, 뇌 외상 피해자에게 제공할 수 있는 잠재적 이점을 입증했습니다.
Annovis Bio (NYSE: ANVS) a obtenu un brevet américain pour traiter les traumatismes crâniens aigus (TBI) avec son principal candidat médicamenteux, le buntanetap. Le brevet (No. 12,042,482) couvre des méthodes pour traiter les TBI et prévenir la mort cellulaire nerveuse. Ce succès renforce le portefeuille d'Annovis Bio, qui comprend des brevets pour l'utilisation de buntanetap dans les maladies neurodégénératives aiguës et chroniques ainsi que dans les troubles mentaux.
La PDG Maria Maccecchini a souligné l'importance de cette étape, mettant en avant le potentiel de buntanetap pour lutter contre la mort des cellules nerveuses dans diverses conditions cérébrales. Des études précliniques sur des modèles animaux de TBI et d'accident vasculaire cérébral ont montré l'efficacité de buntanetap à prévenir la mort cellulaire et la perte de fonction, démontrant ses avantages potentiels pour les victimes de traumatismes crâniens.
Annovis Bio (NYSE: ANVS) hat ein US-Patent zur Behandlung von akuten traumatischen Hirnverletzungen (TBI) mit seinem führenden Wirkstoffkandidaten buntanetap gesichert. Das Patent (Nr. 12,042,482) deckt Methoden zur Behandlung von TBI und zur Verhinderung des Absterbens von Nervenzellen ab. Dieser Erfolg stärkt das Portfolio von Annovis Bio, das Patente für die Verwendung von buntanetap bei akuten und chronischen neurodegenerativen Erkrankungen sowie psychischen Erkrankungen umfasst.
CEO Maria Maccecchini hob die Bedeutung dieses Meilensteins hervor und betonte das Potenzial von buntanetap, das Absterben von Nervenzellen bei verschiedenen Hirnzuständen anzugehen. Präklinische Studien an Tiermodellen für TBI und Schlaganfall haben die Wirksamkeit von buntanetap bei der Verhinderung von Zellsterben und Funktionsverlust gezeigt, was seine potenziellen Vorteile für Opfer von Hirnverletzungen verdeutlicht.
- Secured U.S. patent for treating acute traumatic brain injuries with buntanetap
- Preclinical studies show buntanetap's efficacy in preventing cell death and loss of function in TBI and stroke models
- Strengthened patent portfolio covering various neurodegenerative disorders and mental illnesses
- None.
Annovis Bio Inc. securing a U.S. patent for its lead drug candidate, buntanetap, for the treatment of acute traumatic brain injury (TBI) is a significant achievement in the pharmaceutical domain. Patents are critical in the drug development process as they provide exclusivity, enabling the company to recoup its investment in R&D. This U.S. patent’s approval, following the filing in 2016, indicates robust and substantiated innovation. Investors should note that this patent protects Annovis's intellectual property in a large market, potentially leading to higher valuation due to anticipated exclusive market rights.
Buntanetap’s efficacy in preclinical studies for TBI is an encouraging development. Acute traumatic brain injuries are prevalent and challenging to treat, often resulting in long-term disability. The drug’s potential to prevent nerve cell death is noteworthy because it addresses the primary cause of functional loss in TBI. If clinical trials replicate these preclinical results, buntanetap could become a pivotal treatment in neuroscience. This development places Annovis Bio at the forefront of neurotrauma care, which may increase investor interest and confidence in the company's innovative capabilities.
This patent not only strengthens Annovis Bio’s portfolio but also potentially opens a substantial new market in the U.S. for TBI treatment. The prevalence of TBI, which affects millions annually, means there is a significant demand for effective treatments. A patent secured in the U.S. provides a competitive advantage and enhances the company's appeal as a prospective market leader in neurodegenerative and acute injury treatments. Investors should consider the long-term revenue implications, as successful commercialization of buntanetap could lead to considerable returns.
MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), announced today the issuance of a U.S. patent for methods of treating acute traumatic brain injuries (TBI) with its lead drug candidate, buntanetap.
In 2016, the Company filed a patent covering the treatment of various nerve insults, including TBI, stroke, and nerve and spinal cord injuries. While these claims were granted in Europe and worldwide, the U.S. Patent and Trademark Office (USPTO) required the claims to be divided into individual patents for each indication. Annovis Bio has now received U.S. Patent No. 12,042,482, which covers methods for treating TBI and preventing nerve cell death with buntanetap.
“We are thrilled to achieve this significant milestone for buntanetap,” said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis. “Nerve cell death is a common underlying factor in many brain conditions, beyond just Alzheimer’s and Parkinson’s. Our preclinical studies in TBI and stroke animal models have demonstrated buntanetap’s efficacy in preventing cell death and loss of function, and it is our duty to explore its potential benefits for victims of brain trauma, a prevalent issue in the U.S.”
This patent significantly strengthens Annovis Bio’s portfolio which includes patents and patent applications covering the use of buntanetap for acute and chronic neurodegenerative diseases as well as mental illnesses. The Company's commitment to addressing a broad range of neurodegenerative [MM1] disorders highlight its innovative approach to restoring brain function and improving patient outcomes.
About Buntanetap
Buntanetap (formerly known as Posiphen or ANVS401) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This improves synaptic transmission, axonal transport, and reduces neuroinflammation. Dysregulation of these pathways has been shown to cause nerve cell degeneration and ultimately nerve cell death. By targeting these pathways, buntanetap has the potential to reverse neurodegeneration in Alzheimer’s, Parkinson’s, and other neurodegenerative diseases, thereby aiming to restore brain function and improve the quality of life for patients.
About Annovis Bio, Inc.
Headquartered in Malvern, Pennsylvania, Annovis Bio Inc. is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for Email Alerts at https://www.Annovisbio.com/email-alerts.
Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, the Company's plans related to clinical trials. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include, but are not limited to, those related to patient enrollment, the effectiveness of Buntanetap, and the timing, effectiveness, and anticipated results of the Company's clinical trials evaluating the efficacy, safety, and tolerability of Buntanetap. Additional risk factors are detailed in the Company's periodic filings with the SEC, including those listed in the "Risk Factors" section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements in this press release are based on information available to the Company as of the date of this release. The Company expressly disclaims any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contacts
Annovis Bio, Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
Investor Contact
Scott McGowan
InvestorBrandNetwork (IBN)
Phone: 310.299.1717
IR@annovisbio.com
Investor Website
FAQ
What is the new U.S. patent Annovis Bio (ANVS) received for buntanetap?
What potential benefits does buntanetap show in preclinical studies for TBI and stroke?
How does the new patent strengthen Annovis Bio's (ANVS) portfolio?
What is the significance of buntanetap in treating neurodegenerative disorders?
